Will Obesity Drugs Gain Soon?
Motley Fool
How Doctors Actually Diagnose Obesity
Motley Fool
The Biggest Loser in the Obesity Drug Market
Motley Fool
And the Obesity Plot Thickens
Motley Fool
Key Dates For Arena And Orexigen Investors
Seeking Alpha
What Orexigen Is Saying -- and Not Saying
Motley Fool
FDA Lightens Up on Obesity Drugs
Motley Fool
Orexigen receives dispute response from FDA
The Fly on the Wall